Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2020 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Late-Breaker Oral Presentation at the 32nd EORTC-NCI-AACR Virtual Symposium

NEWARK, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
September 15, 2020 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Appointment of Robert Doebele, MD, PhD as Executive Vice President and Chief Scientific Officer

NEWARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
September 03, 2020 16:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference

NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
September 03, 2020 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Closes $63 Million Series B Financing

NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has closed a...
September 02, 2020 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Exclusive License to the Clinical-Stage MDM2 Inhibitor, DS-3032 (Milademetan) from Daiichi Sankyo

NEWARK, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer,...
August 25, 2020 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway

NEWARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
May 13, 2019 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Present at the UBS Global Healthcare Conference

NEWARK, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...
April 03, 2019 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Presents Preclinical Data on Lead Candidate Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting

NEWARK, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
April 02, 2019 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Presents Preclinical Activity of Tarloxotinib in NRG1 Fusion Cancers at the Annual American Association for Cancer Research (AACR) Meeting

NEWARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
March 19, 2019 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations

NEWARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...